Evidence-based screening protocols for cervical cancer?
Menée à l'aide d'un modèle mathématique intégrant des données statistiques canadiennes, cette étude estime, en fonction du dernier résultat cytologique et du dernier résultat du test HPV (human papillomavirus), l'âge auquel une femme non vaccinée contre le HPV peut ne plus participer au programme de dépistage du cancer du col de l'utérus
A screening trial is nothing more than a proof of principle. Indeed, there are no comparative effectiveness studies in cervical cancer screening that show what the best interval, stopping age, or management of human papillomavirus (HPV)-positive women is in terms of reduction of cervical cancer incidence and mortality. However, one of the most neglected issues in screening research is the age at which we should stop screening, as noted by Talía Malagón and colleagues in The Lancet Oncology. With the introduction of HPV testing in cervical cancer precursor screening, there has been much focus on the age at which to start screening, but no guideline has dealt with the issue of when to stop testing. However, the introduction of a test with a higher sensitivity and longer lead time should necessarily drive the establishment of a lower stopping age than for the Pap test.
The Lancet Oncology , commentaire, 2017